NASDAQ: IRTCIrhythm Technologies Inc Stock
$143.85-1.63 (-1.12%)
Updated Jun 13, 2025
IRTC Price
$143.85
Fair Value Price
-$86.17
Market Cap
$4.59B
52 Week Low
$55.92
52 Week High
$150.00
P/E
-45.81x
P/B
52.99x
P/S
5.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$618.59M
Earnings
-$98.32M
Gross Margin
69.4%
Operating Margin
-13.56%
Profit Margin
-15.9%
Debt to Equity
9.69
Operating Cash Flow
$48M
Beta
1.27
Next Earnings
Jul 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
IRTC Overview
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IRTC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
IRTC
Ranked#50 of 108
Ranked#50 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $29.39 | A | |
| $12.10 | A | |
| $20.07 | A |
Be the first to know about important IRTC news, forecast changes, insider trades & much more!
IRTC News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IRTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IRTC ($143.85) is overvalued by 266.93% relative to our estimate of its Fair Value price of -$86.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IRTC ($143.85) is not significantly undervalued (266.93%) relative to our estimate of its Fair Value price of -$86.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IRTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IRTC due diligence checks available for Premium users.
Valuation
IRTC fair value
Fair Value of IRTC stock based on Discounted Cash Flow (DCF)
Price
$143.85
Fair Value
-$86.17
Undervalued by
266.93%
IRTC ($143.85) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IRTC ($143.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IRTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IRTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-45.81x
Industry
35.6x
Market
31.36x
IRTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
52.99x
Industry
3.99x
IRTC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IRTC's financial health
Profit margin
Revenue
$158.7M
Net Income
-$30.7M
Profit Margin
-19.3%
IRTC's Earnings (EBIT) of -$83.89M... subscribe to Premium to read more.
Interest Coverage Financials
IRTC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$926.1M
Liabilities
$839.4M
Debt to equity
9.69
IRTC's short-term assets ($636.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRTC's long-term liabilities ($728.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRTC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IRTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.9M
Investing
-$38.1M
Financing
$1.7M
IRTC's operating cash flow ($47.53M)... subscribe to Premium to read more.
Debt Coverage Financials
IRTC vs Medical Device Stocks
Irhythm Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.